Nemunaitis, John

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 1,001

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine

RNA Interference and Gene DeliveryCytokine Signaling Pathways and Interactions

Cited by 445

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

Giaccone, G., Bazhenova, L. A., Nemunaitis, J., Tan, M., Juhász, E., Ramlau, R., van den Heuvel, M. M., Lal, R., Kloecker, G. H., Eaton, K. D., et al. (2015) · European Journal of Cancer

Lung Cancer Diagnosis and TreatmentLung Cancer Research Studies

Cited by 279

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

Nemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy

Immunotherapy and Immune ResponsesLung Cancer Treatments and Mutations

Cited by 147